Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Q4 FY2019 Earnings Presentation
20 slides from Jubilant Pharmova's earnings presentation, May 17, 2019
Slide 1: Financial Results Quarter and Full Year Ended March 31, 2019
Financial Results Quarter and Full Year Ended March 31, 2019
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : May, 17, 2019 Time : 05:00 pm IST Replay from : May 17 to May 24, 2019 Dial in No.: +91 22 7194 5757 Playback ID: 05308# 22
Slide 4: Q4/12M'FY19 Results Analysis
Q4/12M’FY19 Results Analysis 33
Slide 5: Chairmen's Message
Chairmen’s Message JUBILANT REPORTS RECORD PERFORMANCE IN FY19 Revenue up 21% YoY to Rs. 9,111 Crore; EBITDA at Rs 1,775 Crores Normalised PAT at Rs 855 Crore with EPS of Rs. 54 per share Q4’FY19 Revenue at Rs. 2,386 Crore up 6% YoY; Normalised PAT at Rs 135 Crore Commenting on the Company’s perform
Slide 6: JLL – FY19 Snapshot
JLL – FY19 Snapshot YoY Highlights FY18 FY19 Change (%) Revenue from Operations Revenue – Geographical Breakup Revenue Pharmaceuticals 3,995 5,324 33% 9,111 Life Science Ingredients 3,328 3,545 7% 9,111 7,518 755 7,518 5,861 1,291 5,861 775 Others 194 242 24% 194 242 1,129 3,545 654 4,624 Total Reve
Slide 7: EBITDA after One-off Adjustments
EBITDA after One-off Adjustments Rs Crore % Change % Change S. No. Q4'FY18 Q4'FY19 YoY FY18 FY19 YoY 1 Reported EBITDA 481 351 (27%) 1,558 1,775 14% 2 One-off Adjustments 18 103 485% 90 157 74% 3 Adjusted EBITDA 498 455 (9%) 1,649 1,932 17% 4 Reported EBITDA Margin 21.3% 14.7% 20.7% 19.5% 5 Adjusted
Slide 8: Pharmaceuticals Segment Highlights – FY19
Pharmaceuticals Segment Highlights – FY19 YoY Pharmaceutical segment’s revenue increased by 33% YoY to Rs 5,324 Crore. Particulars FY18 FY19 Share in overall revenue at 58% up from 53% last year. Ex-Triad revenue grew by Change (%) 23% YoY Revenue Pharmaceuticals 3,995 5,324 33% North America re
Slide 9: LSI Segment Highlights – FY19
LSI Segment Highlights – FY19 YoY LSI segment’s revenue up 7% YoY to Rs 3,545 Crore Particulars FY18 FY19 Change (%) • Revenue growth was led by better price realisation in Life Revenue Science Chemicals and Specialty Intermediates businesses Life Science Ingredients 3,328 3,545 7% • Better perfor
Slide 10: Others Segment Highlights – FY19
Others Segment Highlights – FY19 YoY Geography Wise Revenue Particulars FY18 FY19 Change (%) Revenue 242 Others 194 242 24% Total 194 5 52 Drug Discovery Solutions 176 217 23% 38 7 India Branded Pharmaceuticals 18 25 38% 129 157 EBITDA (9) 4 - 21 28 EBITDA Margin (4.7%) 1.8% FY18 FY19 India North Am
Slide 11: JLL – Q4'FY19 Financial Highlights
JLL – Q4’FY19 Financial Highlights YoY Geography Wise Revenue Highlights Q4FY18 Q4FY19 Change (%) Revenue Pharmaceuticals 1,233 1,399 13% 2,386 Life Science Ingredients 968 912 (6%) Total 2,252 Others 51 74 45% 210 231 332 396 Total Revenue 2,252 2,386 6% EBITDA 1,081 1,177 Pharmaceuticals 304 287 (
Slide 12: Pharmaceuticals Segment Highlights – Q4'FY19
Pharmaceuticals Segment Highlights – Q4’FY19 Particulars Q4’FY18 Q4’FY19 % Change Specialty Pharma 9% YoY revenue growth led by Allergy and Radiopharma businesses Revenue 1,233 1,399 13% Specialty Pharma 638 696 9% Submissions filed to register venom SCIT for use in animals during CDMO 364 446 2
Slide 13: LSI Segment Highlights – Q4'FY19
LSI Segment Highlights – Q4’FY19 Geography Wise Revenue Particulars Q4’FY18 Q4’FY19 % Change Total Revenue 968 912 (6%) EBITDA 187 101 (46%) -6% YoY 912 968 EBITDA Margin (%) 19.3% 11.0% 124 116 200 217 Specialty Intermediates 50 49 Growth in business aided by higher offtake 593 531 GMP certifie
Slide 14: Debt Profile
Debt Profile Particulars 31/03/18 31/03/19 Foreign Currency Loans ($ Mn) ($ Mn) Standalone 9 0 Subsidiaries 358 500 DSCR Total 367 500 8.1 3.6 Rupee Loans (Rs. Crs) (Rs. Crs) 2.3 Standalone 1,007 1,341 Subsidiaries 79 61 Total 1,086 1,402 FY 2017 FY 2018 FY 2019 Gross Debt (Rs. Crs) (Rs. Crs) Standa
Slide 15: Corporate Actions
Corporate Actions In March 2019, Company’s wholly-owned subsidiary Jubilant Pharma Limited, Singapore, issued USD 200 Mn rated unsecured bonds of USD200 million. The Notes bearing interest at 6.00% per annum will Bonds mature in March 2024 In March 2019, the Company fully redeemed the outstandin
Slide 16: Jubilant Life Science – Key Strengths
Jubilant Life Science – Key Strengths 1 Strong Leadership in Key Products and Markets 2 Global Competitive Edge Due to Low Cost and Vertical Integration 3 De-risked Business Model With Diverse Sources of Revenue 4 Strong Pipeline of Products with Deep R&D Capabilities 5 High-Quality, World –Class, L
Slide 17: Jubilant Life Science – Outlook
Jubilant Life Science – Outlook The Company continues to work on its strategic focus on being closer to customers and to further strengthen its leadership position in defined businesses. Expect stable performance at Company level in FY20 • Pharmaceuticals - Expect steady revenues and range bound
Slide 18: Appendix
ee rt JUBHANT LIFESCIENCES Appendix 17
Slide 19: Income Statement – Q4 & 12M'FY19
Income Statement – Q4 & 12M’FY19 Particulars Q4 FY 18 Q4 FY19 YoY Growth 12M FY18 12M FY19 YoY Growth (Rs Crs) (%) (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 2252 2386 6% 7518 9111 21% Pharmaceuticals 1233 1399 13% 3995 5324 33% Life Science Ingredients 968 912 (6%) 3328 3545 7% Othe
Slide 20: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002 Ph: +91 22 6645 1209 E-mail: ravi.agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Gaurav Kashyap Jubilant Life Sciences Limited Perfect Relat
Jubilant Life Sciences — Q4 FY2019 Earnings Presentation on 6ix